Rimonabant

also known as SR141716 · Acomplia · RIMONABANT HYDROCHLORIDE · SR-14171 · SR-141716A · Zimulti

Small molecule targets CNR1 via inhibition

Developed for: obesity disorder · type 2 diabetes mellitus · hyperlipidemia · metabolic syndrome X · atherosclerosis · fatty liver disease · alcohol-related disorders · cardiovascular disorder
+7 more
· coronary atherosclerosis · eating disorder · Prader-Willi syndrome · prediabetes syndrome · proteinuria · schizophrenia · spinal cord injury
Investigated by: Sanofi · National Institute on Drug Abuse (NIDA) · Aristotle University Of Thessaloniki · European Foundation for the Study of Diabetes · National Institute on Alcohol Abuse and Alcoholism (NIAAA) · National Institutes of Health (NIH)
+9 more
· PWSAUSA · Royal Surrey County Hospital NHS Foundation Trust · Sanofi-Synthelabo · Sinfatin S.L · The Scripps Research Institute · University Hospital, Clermont-Ferrand · University of Maryland, Baltimore · University of Surrey · Weill Medical College of Cornell University

Regulatory milestones approvals, filings & regulatory actions · 2 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Withdrawn	EU (EMA)	Zimulti	—	2009-01-16	europa.eu ↗
Approved	EU (EMA)	Zimulti	—	2006-06-19	europa.eu ↗

Trials 44

today

EU approved 2006

NCT07843108 · Ph 1/2 NCT00750347 · Ph 1 NCT00754689 · Ph 3 NCT00690456 · Ph 3 NCT00656487 · Ph 2 NCT00678483 · Ph 3 NCT00577148 · Ph 3 NCT00576667 · Ph 3 NCT00547118 · Ph 2 NCT00546325 · Ph 3 NCT00603109 · Ph 3 NCT00584389 · Ph 4 NCT00478972 · Ph 3 NCT00478595 · Ph 3 NCT00458081 · Ph 3 NCT00449605 · Ph 3 NCT00434096 · Ph 3 NCT00412698 · Ph 3 NCT00405808 · Ph 3 NCT00408148 · Ph 3 NCT00325650 · Ph 3 NCT01041170 · Ph 1 NCT00325546 · Ph 3 NCT00299325 · Ph 3 NCT00288236 · Ph 3 NCT00263042 · Ph 3 NCT00636766 · not/applicable NCT00228176 · Ph 3 NCT00239967 · Ph 3 NCT00257257 · Ph 3 NCT00124332 · Ph 3 NCT00459004 · Ph 2 NCT00458718 · Ph 3 NCT00481975 · Ph 3 NCT00481923 · Ph 3 NCT00464256 · Ph 3 NCT00075205 · Ph 2 NCT00464165 · Ph 3 NCT00459173 · Ph 3 NCT00358228 · Ph 3 NCT00029848 · Ph 3 NCT00386061 · Ph 3 NCT00029835 · Ph 3 NCT00029861 · Ph 3

2001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 12 trials · 1 missed
Phase 1	NCT00750347	Sep → Oct 2008	—	University Hospital, Clermont-Ferrand	Completed	No outcome recorded
Phase 1	NCT01041170	Apr 2006 → Jan 2010	cannabis dependence	National Institute on Drug Abuse (NIDA)	Completed	Missed primary
Phase 1/21 trial
Phase 1/2	NCT07843108	May 2026 → Aug 2027 expected	spinal cord injury	Sinfatin S.L	Active not recruiting	No outcome recorded
Phase 24 trials
Phase 2	NCT00656487	Apr 2008 → Dec 2010	cannabis dependence, substance withdrawal syndrome	The Scripps Research Institute	Completed	No outcome recorded
Phase 2	NCT00547118	Nov 2007 → Mar 2009	hypertensive disorder, obesity disorder, schizoaffective disorder, schizophrenia	University of Maryland, Baltimore	Terminated	No outcome recorded
Phase 2	NCT00459004	Oct 2004 → Apr 2006	obesity disorder	Sanofi	Completed	No outcome recorded
Phase 2	NCT00075205	Dec 2003 → Mar 2007	alcohol-related disorders	National Institute on Alcohol Abuse and Alcoholism (NIAAA)	Completed	No outcome recorded
Phase 335 trials · 4 met primary · 4 missed
Phase 3	NCT00754689	Sep → Nov 2008	type 2 diabetes mellitus	Sanofi	Withdrawn	No outcome recorded
Phase 3	NCT00690456	May 2008 → Feb 2009	type 2 diabetes mellitus	Sanofi	Terminated	No outcome recorded
Phase 3	NCT00678483	Apr → Nov 2008	obesity disorder	Sanofi	Terminated	No outcome recorded
Phase 3	NCT00577148	Feb 2008 → Feb 2009	fatty liver disease	Sanofi	Terminated	No outcome recorded
Phase 3	NCT00576667	Jan 2008 → Feb 2009	fatty liver disease	Sanofi	Terminated	No outcome recorded
Phase 3	NCT00546325	Oct 2007 → Feb 2009	type 2 diabetes mellitus	Sanofi	Completed	No outcome recorded
Phase 3	NCT00603109	Aug 2007 → Jan 2009	Prader-Willi syndrome	Weill Medical College of Cornell University	Terminated	No outcome recorded
Phase 3	NCT00478972	Apr 2007 → Jan 2009	obesity disorder, type 2 diabetes mellitus	Sanofi	Terminated	No outcome recorded
Phase 3	NCT00478595	Apr 2007 → Feb 2009	obesity disorder, type 2 diabetes mellitus	Sanofi	Terminated	No outcome recorded
Phase 3	NCT00458081	Mar 2007 → Jan 2009	hyperlipidemia, obesity disorder, proteinuria, type 2 diabetes mellitus	Sanofi	Terminated	No outcome recorded
Phase 3	NCT00449605	Mar 2007 → Nov 2008	type 2 diabetes mellitus	Sanofi	Terminated	No outcome recorded
Phase 3	NCT00434096	Feb 2007 → Nov 2008	obesity disorder	Sanofi	Terminated	No outcome recorded
Phase 3	NCT00412698	Dec 2006 → Jan 2009	hyperlipidemia, obesity disorder	Sanofi	Terminated	No outcome recorded
Phase 3	NCT00405808	Dec 2006 → Feb 2009	obesity disorder	Sanofi	Terminated	No outcome recorded
Phase 3	NCT00408148	Oct 2006 → Dec 2008	obesity disorder	Sanofi	Terminated	No outcome recorded
Phase 3	NCT00325650	May 2006 → Mar 2009	prediabetes syndrome	Sanofi	Terminated	No outcome recorded
Phase 3	NCT00325546	Apr 2006 → Apr 2007	obesity disorder	Sanofi	Completed	No outcome recorded
Phase 3	NCT00299325	Feb 2006 → Jul 2008	metabolic syndrome X	Sanofi	Completed	Missed primary
Phase 3	NCT00288236	Jan 2006 → Jul 2007	type 2 diabetes mellitus	Sanofi	Completed	No outcome recorded
Phase 3	NCT00263042	Dec 2005 → Apr 2009	cardiovascular disorder	Sanofi	Terminated	Missed primary
Phase 3	NCT00228176	Aug 2005 → Apr 2009	atherosclerosis, metabolic syndrome X, obesity disorder	Sanofi	Terminated	Missed primary
Phase 3	NCT00239967	May 2005 → Feb 2007	hyperlipidemia, obesity disorder	Sanofi	Completed	No outcome recorded
Phase 3	NCT00257257	Mar 2005 → Jun 2006	type 2 diabetes mellitus	Sanofi	Completed	No outcome recorded
Phase 3	NCT00124332	Jan 2005 → Oct 2007	coronary atherosclerosis	Sanofi	Completed	Missed primary
Phase 3	NCT00458718	Sep 2004 → Jul 2005	—	Sanofi	Completed	Met primary
Phase 3	NCT00481975	Aug 2004 → Aug 2005	eating disorder, obesity disorder	Sanofi	Completed	No outcome recorded
Phase 3	NCT00481923	May 2004 → Apr 2005	obesity disorder	Sanofi	Completed	No outcome recorded
Phase 3	NCT00464256	Apr → Nov 2004	—	Sanofi	Completed	No outcome recorded
Phase 3	NCT00464165	Nov 2002 → Oct 2003	—	Sanofi	Completed	No outcome recorded
Phase 3	NCT00459173	Nov 2002 → Sep 2005	—	Sanofi	Completed	No outcome recorded
Phase 3	NCT00358228	Sep 2002 → Aug 2003	—	Sanofi	Completed	No outcome recorded
Phase 3	NCT00029848	Oct 2001 → May 2004	obesity disorder, type 2 diabetes mellitus	Sanofi	Completed	Met primary
Phase 3	NCT00386061	Oct 2001 → Jun 2004	obesity disorder	Sanofi	Completed	Met primary
Phase 3	NCT00029835	Sep 2001 → Nov 2003	hyperlipidemia, obesity disorder	Sanofi	Completed	No outcome recorded
Phase 3	NCT00029861	Aug 2001 → Apr 2004	obesity disorder	Sanofi	Completed	Met primary

Phase 41 trial
Phase 4	NCT00584389	Jul 2007 → Apr 2009	obesity disorder	University of Surrey	Terminated	No outcome recorded
Phase not applicable1 trial
—	NCT00636766	Sep 2005 → Dec 2007	atherosclerosis, metabolic syndrome X, stroke disorder, type 2 diabetes mellitus	Aristotle University Of Thessaloniki	Completed	No outcome recorded
Comparator or background therapy3 trials
Phase 1/2	NCT05398913 Comparator	May 2021 → Jun 2022	spinal cord injury	Hospital Nacional de Parapléjicos de Toledo	Completed	No outcome recorded
Phase 2	NCT05622994 Comparator	Nov 2022 → Nov 2023	spinal cord injury	Hospital Nacional de Parapléjicos de Toledo	Unknown	No outcome recorded
Phase 4	NCT00734123 Background	Apr 2008 → Apr 2009	atherosclerosis	Hospital Arnau de Vilanova	Unknown	No outcome recorded

Evidence & citations 11 cited values

Every value below carries the sentence it was read from. 49 sources stand behind the page.

Field	Value	Cited text
Known as	Rimonabant	“SR141716 (Rimonabant)” NCT00075205 ↗ 46 NCT00458081 ↗ NCT00257257 ↗ NCT00464165 ↗ NCT00449605 ↗ NCT00124332 ↗ NCT00029835 ↗ NCT00408148 ↗ NCT00754689 ↗ NCT00481923 ↗ NCT00656487 ↗ Show 36 more sources
Known as	Acomplia	ChEMBL registry synonym — accepted as the source's own label CHEMBL111 ↗
Known as	RIMONABANT HYDROCHLORIDE	ChEMBL registry synonym — accepted as the source's own label CHEMBL111 ↗
Known as	SR-14171	ChEMBL registry synonym — accepted as the source's own label CHEMBL111 ↗
Known as	SR-141716A	ChEMBL registry synonym — accepted as the source's own label CHEMBL111 ↗
Known as	SR141716	“rimonabant (SR141716)” NCT00459173 ↗ 16 “Rimonabant (SR141716)” NCT00288236 ↗ “rimonabant (SR141716)” NCT00434096 ↗ “rimonabant (SR141716)” NCT00678483 ↗ “Rimonabant (SR141716)” NCT00257257 ↗ “Rimonabant (SR141716)” NCT00029848 ↗ “rimonabant (SR141716)” NCT00481923 ↗ “rimonabant (SR141716)” NCT00458718 ↗ “Rimonabant (SR141716)” NCT00029861 ↗ “Rimonabant (SR141716)” NCT00029835 ↗ “rimonabant (SR141716)” NCT00459004 ↗ Show 6 more sources
Known as	Zimulti	ChEMBL registry synonym — accepted as the source's own label CHEMBL111 ↗
Action	Inhibit	“Rimonabant, a selective cannabinoid-1 receptor (CB1) blocker” PMID 16291982 ↗ Nov 2005 1 “Cannabinoid CB1 receptor antagonist” CHEMBL111 ↗
Modality	Small molecule	— CHEMBL111 ↗
Route	Oral	“Tablet, oral administration” NCT00228176 ↗
Target	CNR1	“Cannabinoid CB1 receptor antagonist” CHEMBL111 ↗